Gmax Biopharm LLC

TOKYO, JAPAN, March 19, 2026 / EINPresswire.com / -- LOTTE Holdings, Co., Ltd. (Tokyo, Japan; CEO: Genichi Tamatsuka, hereinafter “LOTTE Holdings”) announces an investment in Alveus Therapeutics, Inc. (hereinafter “Alveus Therapeutics”), a rapidly emerging clinical stage biotechnology company pioneering next generation therapies for obesity and metabolic diseases. Founded in 2023, Alveus Therapeutics is developing a portfolio of long acting biologics centered on validated incretin and amylin biology. Its lead program, ALV 100, is a novel antibody-peptide fusion protein combining GLP 1 receptor agonism with GIP receptor antagonism. This novel antibody-peptide fusion protein aims to solve the most persistent challenges of current treatment: dosing frequency, patient tolerability, and long-term weight maintenance. Early data suggests that ALV-100 could offer substantial, durable weight reduction and improved metabolic health, all while requiring less frequent dosing. Beyond the lead program, Alveus Therapeutics is also advancing a suite of next generation amylin based therapeutics, including ALV 200, a highly selective amylin receptor agonist currently in IND enabling studies, alongside a pipeline of injectable and oral candidates designed to potentially improve body composition and patient adherence. The Series A is supported by global investors, including New Rhein Healthcare Investors, Andera Partners, Omega Funds, Sanofi Capital, Kurma Partners, Avego BioScience Capital, and Global BioAccess Fund. LOTTE Holdings Healthcare and Biopharmaceutical CVC’s participation reflects our confidence in the company’s scientific approach, experienced leadership team, and the rapidly accelerating global demand for obesity and metabolic disease therapies with a global market projected to surpass $100 billion by 2030 and continue expanding through 2035. “LOTTE Holdings CVC’s investment underscores our commitment to backing transformational healthcare companies grounded in rigorous science,” said Dr. Joon Paek, Managing Partner at LOTTE Holdings Healthcare & Biopharmaceutical CVC. “Alveus Therapeutics’ leadership team consists of industry veterans with deep expertise in biologics and metabolic disease. We are confident they are uniquely positioned to lead the next wave of innovation in this rapidly expanding field.” About LOTTE Holdings Co., Ltd. Company Name: LOTTE Holdings Co., Ltd. Headquarters: 3-20-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan Representative Director: Genichi Tamatsuka Website: https://lotte-hd.com/ CVC Website: https://lotte-hd.com/bio-cvc/english/ LOTTE Holdings engages in a diverse range of businesses, including its core confectionery and ice cream sectors, professional baseball team management, real estate, finance, CVC, hotels, and healthcare. Looking ahead, the company aims to drive further innovation in the food industry and boldly pursue the creation of new businesses by integrating opportunities from both Japan and South Korea. Established in Tokyo, Japan, in 1948 with the manufacturing and sale of chewing gum, the LOTTE Group now operates with headquarters in both Japan and South Korea. The group conducts business across approximately 30 countries and regions worldwide, spanning sectors such as food, distribution, retail, biopharmaceuticals, healthcare, data centers, hotels and resorts, entertainment, and construction. Embracing the unified group vision of “Lifetime Value Creator,” LOTTE Group is committed to continually providing value throughout every stage of people’s lives. About Alveus Therapeutics Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden. Alveus acquired global development and commercialization rights outside of greater China to ALV-100 from Gmax Biopharm International Limited in 2024. Alveus is headquartered in Philadelphia, PA, with research and development operations based in Copenhagen, Denmark. For more information, visit www.alveustx.com Youhei Kawana, Ryo Nagamine LOTTE Holdings Co., Ltd. Communication and PR Department email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Jeito Capital, Novo Holdings and other healthcare investors join Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds Additional capital further supports clinical development of ALV ‑ 100, ALV ‑ 200 and continued advancement of differentiated amylin ‑ based pipeline PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, today announced the second and final closing of its oversubscribed Series A financing, increasing the total round size to $197 million. The second closing includes participation from Jeito Capital, Novo Holdings, and additional healthcare-focused funds, joining the original Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi Capital, Kurma Partners, Avego BioScience Capital, and other life sciences investors. The further funding expands Alveus’ investor base and strengthens the company’s ability to progress multiple development programs in parallel, including the ongoing clinical development of ALV‑100, a bifunctional glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist / glucagon-like peptide-1 receptor (GLP-1R) agonist fusion protein, designed to deliver durable weight loss with improved quality of weight reduction and long‑term maintenance. The incremental financing will support advancement of ALV-200, Alveus’ highly selective amylin receptor 3 (AMYR3) peptide agonist, and progression of its oral amylin program toward clinical development, with the plan to commence first-in-human clinical studies within the next 18 months. “The backing of specialist healthcare investors with deep domain expertise reflects strong momentum for Alveus, driven by our differentiated portfolio, the strength of our team, and the scale of the opportunity in obesity and metabolic disease. Over the next 18 to 24 months, we plan to reach key value inflection points, including delivering a well-characterized Phase 3-ready program and multiple pipeline assets entering early clinical development ,” said Raj Kannan, Chief Executive Officer of Alveus. In conjunction with the closing of the Series A extension, Ksenija Pavletic, General Partner and CCO at Jeito Capital, will join the Alveus Board of Directors. About Alveus Therapeutics Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden. Alveus acquired global development and commercialization rights outside of greater China to ALV-100 from Gmax Biopharm International Limited in 2024. Alveus is headquartered in Philadelphia, PA, with research and development operations based in Copenhagen, Denmark. For more information, visit Investor & Media Contacts Alveus Therapeutics Media Sasha Damouni Ellis, Damouni Group LLC sasha@damounigroup.com Investors Victoria Igumnova, Meru Advisors LLC vigumnova@meruadvisors.com

Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program ALV ‑ 100 designed to deliver potent, durable weight loss and long ‑ term maintenance with improved tolerability The financing will also support Investigational New Drug (IND) filings for several early proprietary development candidates, including its highly selective Amylin peptide agonist (ALV-200) With the global obesity market projected to reach approximately $150 billion by 2030 1 and an estimated 4 billion people affected by 2035 2 , this investment reflects Jeito’s commitment to addressing one of the world’s most pressing health challenges through innovative treatments that offer meaningful benefits to patients Paris, February 24, 2026 – Jeito Capital (“Jeito”), a leading global independent private equity fund dedicated to biopharma, announced today that it was the cornerstone investor in the second closing of the oversubscribed Series A financing of Alveus Therapeutics (“Alveus”), a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases. This closing brings the total amount raised in the Series A round to $197 3 million . Jeito made a significant commitment in the second closing of Series A and was joined by Novo Holdings and other healthcare-focused funds, alongside the original Series A syndicate led by New Rhein Healthcare Investors, Andera Partners, and Omega Funds, with participation from Sanofi, Kurma Partners, Avego BioScience Capital, and other life sciences investors. Founded in 2024 and headquartered in Philadelphia, with R&D operations in Copenhagen, Alveus is building a differentiated pipeline of next-generation obesity and metabolic disease therapies designed to deliver sustainable weight loss with superior tolerability and reduced treatment burden, addressing the critical challenge of weight adherence, a key limitation of current treatments. The company is led by an experienced management team with deep expertise in obesity: Raj Kannan, MBA, CEO of Alveus Therapeutics, has led multiple successful licensing transactions and strategic acquisitions at prior biotech companies, including Chiasma and Aerie Pharmaceuticals. Alveus’ CSO and CBO, Jacob Jeppesen, PhD, and Brian Bloomquist, PhD, have more than 30 years of combined leadership and R&D experience in leading obesity and metabolic drug companies such as Novo Nordisk and Eli Lilly. This financing strengthens Alveus’ ability to advance multiple development programs in parallel. The company’s lead program, ALV-100 is a bifunctional GIPR antagonist / GLP-1R agonist fusion protein that combines GLP-1 agonism and GIRP antagonism. This approach achieves potent metabolic rewiring, durable weight loss and long‑term maintenance with improved tolerability, targeting key limitations of current chronic therapies. Proceeds will support the Phase 2 clinical trials of ALV-100 while also advancing its amylin-based portfolio towards clinical development. Amylin is a hormone that controls satiety and provide additional metabolic benefits. These programs include ALV‑200, Alveus’ highly selective amylin receptor 3 (AMYR3) peptide agonist, and its oral amylin‑based pipeline, leading to additional IND filings and first-in-human phase 1 studies within the next 18 months. In conjunction with the closing of the Series A extension, Ksenija Pavletic, General Partner and CCO of Jeito Capital, will join the Alveus Board of Directors. Ksenija Pavletic, General Partner & Chief Commercial Officer of Jeito Capital, added : “At Jeito, we firmly believe that value creation is always driven by meaningful patient benefit. We have been seeking the right opportunity within the increasingly complex field of obesity, and we are convinced that, given the diversified pipeline, Alveus represents a truly high-potential company. We are delighted to support Alveus’ team in the development of solutions eagerly awaited by millions of patients worldwide, which will provide meaningful benefits.” Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said : “Obesity, one of the defining health challenges of our time, demands innovative treatments that offer real hope to patients. With over three decades of experience and a proven track record with leading innovators in the field, Alveus’ talented leadership team is advancing next-generation therapies, continuously improving their efficacy and tolerability to transform patients’ daily lives. We are excited to partner with such a talented team and to help unlock the full potential of Alveus.” Raj Kannan, Chief Executive Officer of Alveus said : “ The backing of specialist healthcare investors with deep domain expertise reflects strong momentum for Alveus, driven by our differentiated portfolio, the strength of our team, and the scale of the opportunity in obesity and metabolic disease. Over the next 18 to 24 months, we expect to reach key value inflection points, including a well-characterized Phase 3-ready asset and multiple pipeline assets entering early clinical development .” About Jeito Capital Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito has built a diversified portfolio of clinical biopharmas with cutting-edge innovations addressing high unmet needs. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit or follow us on LinkedIn . About Alveus Therapeutics Alveus Therapeutics is a clinical-stage biotechnology company developing next-generation therapies for obesity and metabolic diseases, designed for sustained efficacy, improved tolerability, and reduced treatment burden. Alveus acquired global development and commercialization rights outside of greater China to ALV-100 from Gmax Biopharm International Limited in 2024. Alveus is headquartered in Philadelphia, PA, with research and development operations based in Copenhagen, Denmark. For more information, visit . Contacts: Jeito Capital Rafaèle Tordjman, Founder & CEO Jessica Fadel, EA Tel: +33 6 33 44 25 47 Stéphanie Elbaz Tel: +33 6 46 05 08 07 media@jeito.life ICR Healthcare Mary-Jane Elliott / Emily Johnson Jeito@icrhealthcare.com Tel: +44 (0) 20 3709 5700 Sean Leous sean.leous@icrhealthcare.com Tel: +1 (646) 866 4012 1 2 3 For the 1 st closing of its Series A financing in January 2026, Alveus raised $160 million: